Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Compass Therapeutics, Inc. (NASDAQ:CMPX) has earned an average rating of “Moderate Buy” from the fourteen ratings firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $12.9091.

CMPX has been the subject of a number of recent research reports. Wall Street Zen downgraded shares of Compass Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. William Blair reaffirmed an “outperform” rating on shares of Compass Therapeutics in a research report on Thursday, March 5th. HC Wainwright reaffirmed a “buy” rating and set a $24.00 price objective on shares of Compass Therapeutics in a research report on Monday, April 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Monday, April 20th. Finally, Canaccord Genuity Group lowered their price objective on shares of Compass Therapeutics from $13.00 to $7.00 and set a “buy” rating for the company in a research report on Tuesday, April 28th.

Institutional Investors Weigh In On Compass Therapeutics

A number of institutional investors have recently modified their holdings of the business. Seven Fleet Capital Management LP grew its position in shares of Compass Therapeutics by 65.4% during the 1st quarter. Seven Fleet Capital Management LP now owns 940,538 shares of the company’s stock valued at $4,975,000 after buying an additional 371,791 shares during the last quarter. DV Trading LLC grew its position in Compass Therapeutics by 1,649.8% in the 1st quarter. DV Trading LLC now owns 423,566 shares of the company’s stock worth $2,241,000 after purchasing an additional 399,359 shares during the last quarter. Parallel Advisors LLC bought a new position in Compass Therapeutics in the 1st quarter worth about $28,000. Bank of America Corp DE grew its position in Compass Therapeutics by 224.9% in the 1st quarter. Bank of America Corp DE now owns 865,613 shares of the company’s stock worth $4,579,000 after purchasing an additional 599,179 shares during the last quarter. Finally, Janus Henderson Group PLC bought a new position in Compass Therapeutics in the 1st quarter worth about $294,000. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Stock Performance

CMPX opened at $2.07 on Friday. The company has a 50-day moving average of $2.57 and a 200-day moving average of $4.54. The company has a market capitalization of $372.79 million, a P/E ratio of -5.05 and a beta of 0.89. Compass Therapeutics has a 1-year low of $1.61 and a 1-year high of $6.88.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Tuesday, May 5th. The company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10). As a group, sell-side analysts expect that Compass Therapeutics will post -0.42 earnings per share for the current fiscal year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.